Tetraphase Pharmaceuticals, Inc.

BARDA Awards Contract Worth up to $67 Million for the Development of a Novel Tetraphase Antibiotic

BARDA Awards Contract Worth up to $67 Million for the Development of a Novel Tetraphase Antibiotic

February 16, 2012

WATERTOWN, Mass., Feb 16, 2012 (BUSINESS WIRE) -- Tetraphase Pharmaceuticals, Inc., a clinical-stage life science company developing a portfolio of potent new antibiotics designed to be effective against dangerous, drug-resistant bacteria, including multidrug-resistant (MDR) gram-negative pathogens, today announced that the Biomedical Advanced Research and Development Authority (BARDA) has awarded a contract worth up to $67 million for the development of TP-434, a potent new antibiotic effective against multidrug-resistant gram-negative pathogens and the lead product

Quanterix to Collaborate With the Forsyth Institute and Beth Israel Deaconess Medical Center to Develop Tuberculosis Test

Quanterix to Collaborate With the Forsyth Institute and Beth Israel Deaconess Medical Center to Develop Tuberculosis Test

February 9, 2012

CAMBRIDGE, MA – February 9, 2012 – Quanterix Corporation, a company enabling a new generation of molecular diagnostic tests based on its revolutionary Single Molecule Array (SiMoA™) technology, announced today that it will apply its cutting-edge technology towards the development of an improved test to aid in the diagnosis of active tuberculosis (TB).

BG Medicine, Inc.

BG Medicine, Inc. Appoints Brian S. Posner to its Board of Directors

BG Medicine, Inc. Appoints Brian S. Posner to its Board of Directors

February 13, 2012

WALTHAM, Mass., February 13, 2012 (GLOBE NEWSWIRE) -- BG Medicine, Inc. (Nasdaq:BGMD), a company focused on the development and commercialization of novel, biomarker-based diagnostics, announced the appointment of  Brian S. Posner to its Board of Directors. Mr.

BG Medicine, Inc.

BG Medicine Announces Positive Pivotal Validation Study Results for CardioSCORE, a New Diagnostic Blood Test to Identify Individuals at High Risk for Near-term Major Cardiovascular Events

BG Medicine Announces Positive Pivotal Validation Study Results for CardioSCORE, a New Diagnostic Blood Test to Identify Individuals at High Risk for Near-term Major Cardiovascular Events

February 13, 2012

Waltham, MA, February 13, 2012 -- BG Medicine, Inc.

T2 Biosystems, Inc.

T2 Biosystems Announces Issuance of Key Patent Providing Broad Intellectual Property Protection for Direct Detection Diagnostic Methods

T2 Biosystems Announces Issuance of Key Patent Providing Broad Intellectual Property Protection for Direct Detection Diagnostic Methods

February 2, 2012

Lexington, MA – T2 Biosystems, a company developing direct detection products enabling superior diagnostics, today announced the issuance of patent number 8,102,176 by the United States Patent and Trademark Office entitled

Joule Unlimited, Inc.

JOULE ELECTS ANATOLY CHUBAIS TO BOARD OF DIRECTORS

JOULE ELECTS ANATOLY CHUBAIS TO BOARD OF DIRECTORS

February 2, 2012

THE RUSSIA FORUM – Moscow, Russia – February 2, 2012 – Joule today announced the election of Anatoly Chubais to its board of directors, adding the expertise and insight of a prominent figure in international business, economics and government. The news was released in conjunction with Joule’s participation at the Russia Forum, an annual meeting of high-profile international economists and business leaders.

Avedro, Inc.

Avedro Announces Canadian Approval for Lasik Xtra™

Avedro Announces Canadian Approval for Lasik Xtra™

January 31, 2012

WALTHAM, Mass.--(BUSINESS WIRE)--Avedro, Inc. announced today that the Company’s proprietary Lasik Xtra procedure has received Canadian Approval. Lasik Xtra is a two minute procedure used in conjunction with standard Lasik to restore biomechanical integrity and strength to the cornea after a standard Lasik procedure. The procedure combines riboflavin ophthalmic solution with Avedro’s KXL™ System (UVA irradiation) to achieve accelerated corneal cross-linking during a Lasik procedure.

Affinnova, Inc.

Affinnova Launches Concept Studio for Collaborative Innovation

Affinnova Launches Concept Studio for Collaborative Innovation

January 26, 2012

WALTHAM, Mass., Jan 26, 2012 -- Today - at the Online Research Methods conference in London - Affinnova, Inc., the global leader in marketing innovation software and services, introduced Affinnova Concept Studio, a web-based application that accelerates concept collaboration and development for new products, designs and ad campaigns.

BARDA biothreat contract could bring $40M to Tetraphase

BARDA biothreat contract could bring $40M to Tetraphase

January 25, 2012

Synthetic chemistry company Tetraphase Pharmaceuticals Inc. of Watertown could get $40 million from a federal contract to develop an antibiotic to potentially treat illnesses resulting from biological threats such as anthrax, tularemia or pestis, the company told Mass High Tech in an interview.

Click on Mass High Tech logo to view full article

 

 

Oasys Water, Inc.

Oasys Water Appoints Bob Muscat as New Chief Executive Officer to Drive Commercialization

Oasys Water Appoints Bob Muscat as New Chief Executive Officer to Drive Commercialization

January 23, 2012

BOSTON -- Oasys Water, a leader in forward osmosis technology for desalination, brine recovery and water reuse, today announced the appointment of Bob Muscat as Chief Executive Officer. The appointment marks the beginning of the company’s commercialization phase.